Clinical Research and Trials

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. Learn more about clinical trials by visiting

For more information on clinical studies, contact Beth Ann Brundage, RN, OCN, at 518-926-6644 or Nannette Oberhelman, at 518-926-6701.

Clinical Trials


CTSU A222004
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia


CTSU    A032001  

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer


CTSU A011801      
he CompassHER2 trials (COMprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib


A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer. (Also under Registries)

CTSU A012103

OptimICE-PCR: DeEscalation of Therapy in Early Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy



Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

CTSU A022004

Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer


CTSU  S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab vs. DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study


SCLC Limited

CTSU S1827
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

NSCLC Limited

Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512 
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU A081801
Integration of immune-therapy into adjuvant therapy for resected NSCLC: ALCHEMIST

CTSU EA5181  
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

NSCLC Advanced

Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer


The National Myelodysplastic Syndromes (MDS) Study: Recruiting Patients With Low Blood Counts Undergoing A Bone Marrow Assessment for Evaluation of MDS


Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell


Lab Study

CTSU A212102

Blinded Reference Set for Multicancer Early Detection Blood Tests; Bloods,Tissue;QOL, PEP



A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)


A031902 (CASPAR)
A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer (Temporarily suspended as of 4/10/23)

CTSU GU009  
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

CTSU GU010  
Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

CTSU S1802  
Phase III Randomized Trial of Standard Systemic Therapy (SST) vs. Standard Systemic Therapy Plus Definitive Treatment (Surgery or RT) of the Primary Tumor in Met. Prostate Cancer


CTSU A031704
Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]


P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

NOTE:  Other studies are available to us through the University of VT; we open them as Research Nurse identifies an eligible patient.

C.R. Wood Cancer Center
Research Office

Pruyn Pavilion at Glens Falls Hospital
2nd Floor
100 Park Street
Glens Falls, NY 12801

Phone: 518-926-6701
Fax: 518-926-1954

Clinical Trial Key:

A = Alliance (CALGB, ECOG, SWOG)


CTSU= NCI Cancer Trials Support Unit

P = Pharmacy

Updated 3/2023